The development of safe and effective cell and gene therapies (CGTs) relies on regulatory compliance and critical selection and qualification of raw materials. Regulatory classifications …
The deal with Appia is yet another step in Gilead’s efforts to become an oncology powerhouse — a strategy the company has made clear through …
